Document is current
Any future updates will be listed below
-
Authors
Harris, Stewart
Cimino, Sal
Nguyen, Yen
Szafranski, Kirk
Poon, Yeesha https://orcid.org/0000-0002-4290-832X
-
Funding
Funding for this research was provided by:
Abbott Diabetes Care
- License Information
-
More Information
Article History
Received: 18 October 2024
Accepted: 22 November 2024
First Online: 17 December 2024
Declarations
:
: Stewart Harris reports consulting with Abbott, Bayer, Dexcom, Eli Lilly, Novo Nordisk, and Sanofi and research grants from BIO, Eli Lilly, Novo Nordisk, and Novartis. Sal Cimino is a clinical pharmacist and a senior consultant at MORSE Consulting, which has received an honorarium from Abbott to participate in an advisory board for this study. Yen Nguyen is a clinical pharmacist and the president of Synergyx Consulting, which has received an honorarium from Abbott to participate in an advisory board for this study. Yeesha Poon is an employee and shareholder of Abbott. Kirk Szafranski is an employee of Eversana, which has received project funding from Abbott.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. The clinical trials from which data were taken for this analysis were conducted in accordance with the Declaration of Helsinki, with the relevant consents obtained from all study participants.
